April 7, 2023
Kowa said on April 6 that it has launched another global PIII study for its Rho kinase inhibitor ripasudil (K-321) as an ophthalmic solution to treat Fuchs endothelial corneal dystrophy (FECD), in addition to an ongoing PIII trial targeting a...read more